Ibrutinib-associated Serositis in Mantle Cell Lymphoma
Overview
Overview
Journal
Am J Respir Crit Care Med
Specialty
Critical Care
Date
2019 Feb 26
PMID
30802411
Citations
2
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Barton J, Bertoli L, Cavender J Cureus. 2025; 17(1):e77872.
PMID: 39991333 PMC: 11846498. DOI: 10.7759/cureus.77872.
Erblich T, Manisty C, Gribben J Case Rep Hematol. 2024; 2024:2312182.
PMID: 39015770 PMC: 11251797. DOI: 10.1155/2024/2312182.
Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database.
Allouchery M, Tomowiak C, Lombard T, Perault-Pochat M, Salvo F Front Pharmacol. 2021; 12:769315.
PMID: 34776981 PMC: 8580940. DOI: 10.3389/fphar.2021.769315.
References
1.
Ryan C, Sahaf B, Logan A, OBrien S, Byrd J, Hillmen P
. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016; 128(25):2899-2908.
PMC: 5179333.
DOI: 10.1182/blood-2016-06-715284.
View
2.
Thorp B, Badoux X
. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leuk Lymphoma. 2017; 59(2):311-320.
DOI: 10.1080/10428194.2017.1339874.
View
3.
Lee C, Rattu M, Kim S
. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. J Oncol Pharm Pract. 2014; 22(1):92-104.
DOI: 10.1177/1078155214561281.
View
4.
Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles F
. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009; 4(2):99-105.
DOI: 10.1007/s11523-009-0110-4.
View
5.
Burger J, Tedeschi A, Barr P, Robak T, Owen C, Ghia P
. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373(25):2425-37.
PMC: 4722809.
DOI: 10.1056/NEJMoa1509388.
View